U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, in a deal that would value the joint company at roughly $400 billion, the Financial Times reported on Sunday. It’s still unclear whether the deal will come together, but the companies have been discussing a merger over the last few months, sources told the FT. The merger would be one of the largest in history.
Read the full article: AstraZeneca in Talks with Bristol Myers Squibb on $400B Megadeal, FT Reports //
Source: https://www.cnbc.com/2026/08/02/astrazeneca-and-bristol-myers-squibb-mull-400-billion-deal-report-.html